Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
Condition:   Multiple Sclerosis, Relapsing-Remitting Intervention:   Drug: Cladribine 10 mg oral tablet Sponsors:   Pontificia Universidade Católica do Rio Grande do Sul;   Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials